A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Running, not enrolling · Phase 1
Conditions studied: Advanced Solid Tumors
In brief
The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
Key facts
- Study ID
- NCT06131398
- Run by
- Amgen
- People needed
- 77
- Starts
- 2024-03-07
- Expected to finish
- 2026-07-21
- Last updated by the study team
- 2026-05-28
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- Institut Bergonie — Bordeaux, France
- Gustave Roussy — Villejuif, France
- National Cancer Center Hospital East — Kashiwa-shi, Chiba, Japan
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research — Koto-ku, Tokyo, Japan
- Radboud Universitair Medisch Centrum — Nijmegen, Netherlands
- Erasmus Medisch Centrum — Rotterdam, Netherlands
- Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy — Warsaw, Poland
- Seoul National University Hospital — Seoul, South Korea
- Asan Medical Center — Seoul, South Korea
- Hospital Universitari Vall d Hebron — Barcelona, Catalonia, Spain
- Hospital Clinic i Provincial de Barcelona — Barcelona, Catalonia, Spain
- Hospital Universitario Ramon y Cajal — Madrid, Spain
- Istituto Oncologico della Svizzera Italiana — Bellinzona, Switzerland
- Kantonsspital Sankt Gallen — Sankt Gallen, Switzerland
- National Taiwan University Hospital — Taipei, Taiwan
- Taipei Veterans General Hospital — Taipei, Taiwan
- St Vincents Hospital Sydney — Darlinghurst, New South Wales, Australia
- City of Hope National Medical Center — Duarte, California, United States
- Alliance for Multispecialty Research - Kansas City — Merriam, Kansas, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Washington University — St Louis, Missouri, United States
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
- South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States
- The Queen Elizabeth Hospital — Woodville South, South Australia, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.